Clinical Report: Multisystem Inflammatory Syndrome in Children (MIS-C) Overview
Overview
MIS-C is a rare but serious post-COVID-19 hyperinflammatory syndrome in children characterized by fever, multiorgan involvement, and elevated inflammatory markers. Management focuses on immunomodulation with IVIG, corticosteroids, and biologics, alongside supportive care and thromboprophylaxis, with most patients recovering fully.
Background
MIS-C emerged during the COVID-19 pandemic as a delayed hyperinflammatory condition occurring 2 to 6 weeks after SARS-CoV-2 infection in children. It presents with persistent fever, shock, and multisystem involvement, often mimicking other inflammatory diseases like Kawasaki disease. The syndrome carries a mortality rate of approximately 1%–2%, higher than COVID-19 itself in children, underscoring the need for prompt diagnosis and treatment. Despite multiple guidelines, consensus on management remains limited due to diagnostic ambiguity and heterogeneous presentations.
Data Highlights
Parameter
Value
Source
Incidence of MIS-C
5 cases per million person-months
US early pandemic data
Incidence per SARS-CoV-2 infections
316 cases per million infections (under 21 years)
US early pandemic data
MIS-C Mortality
1%–2%
Multiple studies
Fever duration for diagnosis
>24 hours, >38.0°C
CDC criteria
Typical onset after infection
2 to 6 weeks
CDC/WHO
Key Findings
MIS-C is defined by fever, elevated inflammatory markers, and multisystem involvement following SARS-CoV-2 infection.
Clinical features overlap with Kawasaki disease and other inflammatory conditions, complicating diagnosis.
Immunomodulatory therapy with intravenous immunoglobulin (IVIG), corticosteroids, and biologics is central to treatment.
Thromboprophylaxis is often necessary due to increased thromboembolic risk.
Extracorporeal membrane oxygenation (ECMO) may be required in refractory cardiorespiratory failure cases.
Long-term follow-up is essential to monitor persistent cardiac, gastrointestinal, and neurologic complications.
Clinical Implications
Clinicians should maintain a high index of suspicion for MIS-C in children presenting with persistent fever and multisystem inflammation post-COVID-19. Early initiation of immunomodulatory therapy and supportive care improves outcomes. Given the thromboembolic risk, thromboprophylaxis should be considered, and severe cases may require advanced interventions such as ECMO. Long-term monitoring is critical to detect and manage sequelae.
Conclusion
MIS-C represents a serious postinfectious complication of COVID-19 in children requiring timely recognition and multidisciplinary management. Despite advances, standardized treatment protocols and diagnostic clarity remain areas for ongoing research.
References
CDC 2023 -- MIS-C Diagnostic Criteria and Management
Cohen et al 2022 -- Impact of SARS-CoV-2 Variants on MIS-C Incidence
American College of Rheumatology 2021 -- MIS-C Treatment Guidelines
Royal College of Pediatrics and Child Health 2020 -- MIS-C Definition and Diagnosis
